Princeton Online: Princeton, New Jersey: Premier community information web site
Princeton NJ Health Care Guide
« August 2017 »
30 31 1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31 1 2
3 4 5 6 7 8 9
Follow us on:
Princeton Online on Facebook
Princeton Online on Twitter
Princeton Online on Instagram

Health Guide Press Releases

Hunterdon Regional Cancer Center Among First in the Nation to Treat Advanced Prostate Cancer Patients with PROVENGE

Hunterdon Regional Cancer Center is among the first sites in the nation
to treat advanced prostate cancer patients with PROVENGE®
(sipuleucel-T), the first in a new therapeutic class known as autologous
cellular immunotherapies.  PROVENGE was approved by the U.S. Food and
Drug Administration (FDA) for the treatment of men with asymptomatic or
minimally symptomatic metastatic castrate resistant (hormone refractory)
prostate cancer and is made by Dendreon Corporation.

 PROVENGE is an autologous (made from a patient’s own immune cells)
cellular immunotherapy designed to stimulate a patient’s immune system
to identify and target prostate cancer cells. Each dose is manufactured
specifically for each patient using his immune cells.

PROVENGE is intended solely for autologous use and is not routinely
tested for transmissible infectious diseases.

In controlled clinical trials, serious adverse events reported in the
PROVENGE group included acute infusion reactions (occurring within 1 day
of infusion) and cerebrovascular events.  Severe (Grade 3) acute
infusion reactions were reported in 3.5% of patients in the PROVENGE
group.  Reactions included chills, fever, fatigue, asthenia, dyspnea,
hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache,
nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were
reported in patients in the PROVENGE group.

The most common adverse events (incidence ≥15%) reported in the
PROVENGE group are chills, fatigue, fever, back pain, nausea, joint
ache, and headache.

Please see full Prescribing Information for PROVENGE at

About Prostate Cancer
According to the American Cancer Society, prostate cancer is the most
common non-skin cancer in the United States and the third most common
cancer worldwide. More than two million men in the United States have
prostate cancer, with an estimated 217,730 new cases and approximately
32,050 men expected to die from the disease in 2010.

Individuals interested in learning whether PROVENGE is an appropriate
treatment option should contact Hunterdon Regional Cancer Center at
1-888-788-1260 or call 1-877-336-3736.  For full Prescribing
Information, please visit

Hunterdon Regional Cancer Center is a partner of Fox Chase Cancer
Center. Its comprehensive services include chemotherapy, radiation
therapy, clinical research, early detection and screening programs,
support groups, educational programs, nutrition counseling, psychosocial
support, complimentary therapies and cancer risk assessment.


Add a Comment

Specialized Physical Therapy, LLC
St. Lawrence Rehabilitation Center

  • Disclaimer and Privacy Policy
  • Login
© Princeton Online. All Rights Reserved.
Phone: 609-737-7901 Fax: 609-737-2512